These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 21068716

  • 1. Introduction of a new semi-quantitative index with predictive implications in patients with painful osseous metastases after (186)Re-HEDP therapy.
    Zafeirakis A, Zissimopoulos A, Baziotis N, Limouris GS.
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):91-102. PubMed ID: 21068716
    [Abstract] [Full Text] [Related]

  • 2. Treatment of metastatic bone pain using the bone seeking radiopharmaceutical Re-186-HEDP.
    De Klerk JM, Zonnenberg BA, Blijham GH, Van Het Schip AD, Hoekstra A, Han SH, Quirijnen JM, Van Dijk A, Van Rijk PP.
    Anticancer Res; 1997 Feb; 17(3B):1773-7. PubMed ID: 9179233
    [Abstract] [Full Text] [Related]

  • 3. Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo.
    Maxon HR, Schroder LE, Hertzberg VS, Thomas SR, Englaro EE, Samaratunga R, Smith H, Moulton JS, Williams CC, Ehrhardt GJ.
    J Nucl Med; 1991 Oct; 32(10):1877-81. PubMed ID: 1717669
    [Abstract] [Full Text] [Related]

  • 4. [Pain therapy with rhenium-186 HEDP in multiple bone metastases].
    Palmedo H, Bender H, Schomburg A, Grünwald F, Schöneich G, Zamorra P, Reichmann K, Dierke-Dzierzon C, Mallmann P, Biersack HJ.
    Nuklearmedizin; 1996 Apr; 35(2):63-7. PubMed ID: 8721578
    [Abstract] [Full Text] [Related]

  • 5. [Comparison of rhenium-188, rhenium-186-HEDP and strontium-89 in palliation of painful bone metastases].
    Liepe K, Franke WG, Kropp J, Koch R, Runge R, Hliscs R.
    Nuklearmedizin; 2000 Sep; 39(6):146-51. PubMed ID: 11057405
    [Abstract] [Full Text] [Related]

  • 6. Serum hemoglobin levels predict response to strontium-89 and rhenium-186-HEDP radionuclide treatment for painful osseous metastases in prostate cancer.
    van der Poel HG, Antonini N, Hoefnagel CA, Horenblas S, Valdes Olmos RA.
    Urol Int; 2006 Sep; 77(1):50-6. PubMed ID: 16825816
    [Abstract] [Full Text] [Related]

  • 7. 186Re-etidronate. Efficacy of palliative radionuclide therapy for painful bone metastases.
    Han SH, De Klerk JM, Zonnenberg BA, Tan S, Van Rijk PP.
    Q J Nucl Med; 2001 Mar; 45(1):84-90. PubMed ID: 11456380
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The PLACORHEN study: a double-blind, placebo-controlled, randomized radionuclide study with (186)Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases. Placebo Controlled Rhenium Study.
    Han SH, de Klerk JM, Tan S, van het Schip AD, Derksen BH, van Dijk A, Kruitwagen CL, Blijham GH, van Rijk PP, Zonnenberg BA.
    J Nucl Med; 2002 Sep; 43(9):1150-6. PubMed ID: 12215552
    [Abstract] [Full Text] [Related]

  • 12. Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases.
    Küçük NO, Ibiş E, Aras G, Baltaci S, Ozalp G, Bedük Y, Canakci N, Soylu A.
    Ann Nucl Med; 2000 Aug; 14(4):239-45. PubMed ID: 11023023
    [Abstract] [Full Text] [Related]

  • 13. Application of rhenium-188 HEDP in bone metastases therapy.
    Scheffler J, Derejko M, Bandurski T, Romanowicz G.
    Nucl Med Rev Cent East Eur; 2003 Aug; 6(1):55-7. PubMed ID: 14600935
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer.
    Kolesnikov-Gauthier H, Carpentier P, Depreux P, Vennin P, Caty A, Sulman C.
    J Nucl Med; 2000 Oct; 41(10):1689-94. PubMed ID: 11037999
    [Abstract] [Full Text] [Related]

  • 15. Palliative therapy using rhenium-186-HEDP in painful breast osseous metastases.
    Limouris GS, Shukla SK, Condi-Paphiti A, Gennatas C, Kouvaris I, Vitoratos N, Manetou A, Dardoufas C, Rigas V, Vlahos L.
    Anticancer Res; 1997 Oct; 17(3B):1767-72. PubMed ID: 9179232
    [Abstract] [Full Text] [Related]

  • 16. Management of metastatic bone pain with repeated doses of rhenium 186-HEDP in patients under therapy with zoledronic acid: a safe and additively effective practice.
    Zafeirakis A, Zissimopoulos A, Baziotis N, Limouris GS.
    Cancer Biother Radiopharm; 2009 Oct; 24(5):543-50. PubMed ID: 19877884
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases.
    de Klerk JM, van Dijk A, van het Schip AD, Zonnenberg BA, van Rijk PP.
    J Nucl Med; 1992 May; 33(5):646-51. PubMed ID: 1373767
    [Abstract] [Full Text] [Related]

  • 19. Re-186(Sn) HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer.
    Maxon HR, Schroder LE, Thomas SR, Hertzberg VS, Deutsch EA, Scher HI, Samaratunga RC, Libson KF, Williams CC, Moulton JS.
    Radiology; 1990 Jul; 176(1):155-9. PubMed ID: 1693784
    [Abstract] [Full Text] [Related]

  • 20. Treatment efficacy of combined biphosphonates and 186Re-HEDP treatment in cancer patients with bone metastases.
    Koutsikos J, Leondi A.
    Eur J Nucl Med Mol Imaging; 2008 Jul; 35(7):1392-3; author reply 1394-5. PubMed ID: 18438661
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.